BiotechTube
Maxion Therapeutics

Maxion Therapeutics

Cambridge, United Kingdom· Est.
maxiontherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $72M

Overview

Maxion Therapeutics is a private, pre-clinical stage biotech leveraging its novel KnotBody® platform to create antibody-based therapeutics against historically challenging ion channel and GPCR targets. The company combines the target-binding properties of cysteine-rich knottin miniproteins with the favorable drug-like properties of antibodies to address large markets inadequately served by small molecules. Led by an experienced team with strong antibody engineering pedigrees and backed by a syndicate of prominent life science investors, Maxion aims to unlock a new class of biologics for debilitating diseases.

Chronic PainAutoimmunityCardiovascular Disease

Technology Platform

KnotBody® technology: A proprietary platform that fuses naturally occurring cysteine-rich knottin miniproteins into antibody binding loops, creating bifunctional biologics designed to target ion channels and GPCRs with high selectivity and the favorable pharmacokinetic properties of antibodies.

Funding History

1
Total raised:$72M
PIPE$72M

Opportunities

The opportunity lies in applying a validated biologic format (antibodies) to two of the largest target classes in human disease, which have been poorly served by small molecules.
Success could create new, best-in-class treatments for millions of patients with chronic pain, autoimmune, and cardiovascular conditions, representing multi-billion dollar market opportunities.
Strategic interest from an investor like Eli Lilly also opens potential for future lucrative partnerships or acquisition.

Risk Factors

Key risks include the unproven clinical validity of the novel KnotBody® platform, the long and high-attrition development path for any therapeutic program, and the need for significant future capital to fund clinical trials.
The company also operates in a highly competitive landscape where other modalities are advancing against similar targets.

Competitive Landscape

Maxion competes with other biotechs and large pharma developing biologics, peptides, and other modalities for ion channels and GPCRs. While the knottin-antibody fusion approach is unique, competitors include companies using alternative engineered protein scaffolds, nanobodies, or mRNA-based approaches to target these challenging proteins. Its edge lies in the specific evolutionary properties of knottins and the team's deep antibody engineering expertise.

More companies in Biologics / Biosimilars →More companies in United Kingdom →